Palantir's DoD contracts, strong Q1 2025 growth, and competitive edge in AI-driven platforms make it a standout growth ...

Pure Cycle has evolved from a water utility to a land developer, leveraging valuable water assets and the Sky Ranch ...

Voyager struggles with a negative enterprise value, financial risks, and limited catalysts in a competitive Alzheimer's ...

Kestra Medical Technologies, Ltd. sees sales growth but struggles with losses and slowing revenue. Click for risks tied to ...

Discover the best long-term investment strategy for wealth building. Click as I share two alternative dividend ETFs that ...

Blue Owl Capital Corporation outperforms with a 2% Q1 NAV return, solid portfolio quality, low non-accruals & first-lien ...

Explore REGENXBIO's RGX-121 gene therapy for Hunter syndrome, with an FDA decision due Nov 9, 2025. Click here to read my ...

Explore the explosive fallout between Elon Musk and Donald Trump, from political endorsements to shocking allegations, and ...

The backlog for contract oil driller Valaris remains strong. Read why recent share buybacks signal management’s confidence ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

Discover 2 reliable dividend growers with remarkable growth potential. Boost your cash flow passively by focusing on ...

Urbana Corporation is family controlled, which explains some NAV discount, and private markets are not very liquid, but it's ...